Vortioxetine (Trintellix) Dosing and Safety
Start vortioxetine at 10 mg once daily, increase to 20 mg daily as tolerated for optimal efficacy, with 5 mg daily reserved only for patients who cannot tolerate higher doses. 1
Starting Dose
- Standard starting dose: 10 mg once daily 1
- Can be taken without regard to meals 1
- No food effect on pharmacokinetics 2
Titration Schedule
For patients randomized to 15 mg or 20 mg daily, titrate up from 10 mg after the first week 1. The full antidepressant effect is generally not seen until Week 4 or later, with effects typically starting at Week 2 1.
Maximum Dose
- Standard maximum: 20 mg once daily 1
- CYP2D6 poor metabolizers: Maximum 10 mg daily 1
- The 20 mg dose demonstrated superior efficacy in U.S. studies compared to lower doses 1, 3
Dose Considerations by Population
Elderly Patients (≥65 years)
- 5 mg daily was effective in elderly patients (ages 64-88 years) 1
- No dose adjustment required based on age alone 1, 3
- Well tolerated in patients ≥55 years with no clinically significant changes in vital signs, ECG, or body weight 4
Hepatic Impairment
- No dose adjustment needed for mild to moderate hepatic impairment 3, 5
- No clinically meaningful differences in vortioxetine exposure across varying degrees of hepatic impairment 5
Renal Impairment
- No dose adjustment required 3, 5
- No clinically meaningful differences in exposure across varying degrees of renal function 5
Discontinuation
Vortioxetine can be discontinued abruptly, but for doses of 15 mg or 20 mg daily, reduce to 10 mg daily for one week prior to full discontinuation to minimize potential withdrawal symptoms 1, 3. Discontinuation symptoms assessed by the Discontinuation-Emergent Signs and Symptoms scale were comparable to placebo in the first and second weeks after abrupt discontinuation 6.
Safety Profile
Common Adverse Events (≥5% incidence)
- Nausea (21-31%) - most common, dose-dependent 6
- Headache
- Diarrhea
- Dizziness
- Dry mouth
- Constipation
- Fatigue
- Vomiting (3-7%) 6
Key Safety Considerations
Withdrawal rates due to adverse events were low: 4.5-7.8% across vortioxetine doses (5-20 mg) compared to 3.6% for placebo 6. This compares favorably to venlafaxine XR (14.2%) and duloxetine (8.8%) 6.
- Sexual dysfunction: 1.6-1.8% (comparable to placebo at 1.0%) 6
- Insomnia-related events: 2.0-5.1% (placebo 4.0%) 6
- Serious adverse events: 1.2% (placebo-level incidence) 6
- No clinically relevant effects on ECG parameters, including QTcF interval 6
- No effect on clinical laboratory parameters, blood pressure, or heart rate 6
- Mean weight gain in long-term treatment: 0.7-0.8 kg 6
Drug Interactions
Dose adjustment required only for:
- Strong CYP2D6 inhibitors (e.g., bupropion): Reduce vortioxetine dose by half 2
- Broad CYP inducers (e.g., rifampin): May require dose increase 2
No clinically meaningful interactions with other evaluated drugs 2. Vortioxetine is metabolized by multiple CYP450 enzymes (primarily CYP2D6, with contributions from CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8, and CYP2B6) 2.
Clinical Efficacy by Dose
The 20 mg dose consistently showed superior efficacy in U.S. studies 1, 3. Two U.S. studies of the 5 mg dose failed to show effectiveness 1. The 10 mg dose showed efficacy in non-U.S. studies but had mixed results in U.S. trials 1.
Dose-response analysis indicates:
- 50% effective dose: 4.37 mg/day
- 95% effective dose (near-maximal): 17.93 mg/day
- Plateau may not be reached at 20 mg/day, suggesting potential benefit at higher doses 7
Common Pitfall
Do not routinely start at 5 mg daily—this dose failed to demonstrate efficacy in U.S. studies and should only be considered for patients who cannot tolerate 10 mg or higher 1, 3.